Equities

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

  • Revenue in USD (TTM)31.01bn
  • Net income in USD954.00m
  • Incorporated1933
  • Employees30.00k
  • Location
    Bristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
  • Phone+1 (212) 546-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vertex Pharmaceuticals Incorporated4.82bn1.51bn75.48bn3.00k50.5211.6746.6615.665.765.7618.4324.940.62443.807.511,606,498.0019.585.4823.626.9987.2487.5031.359.033.42--0.07620.0036.5948.30119.39--8.06--
Gilead Sciences, Inc.22.72bn4.96bn95.77bn11.80k19.634.3415.134.223.893.8917.8617.600.37064.986.321,925,085.008.0518.079.4821.8879.3783.4221.7239.312.9221.200.520725.341.46-2.04-1.34-14.958.17--
Bristol-Myers Squibb Co31.01bn954.00m133.82bn30.00k73.102.6826.354.320.8090.80916.6522.060.37794.645.261,033,533.001.198.561.4411.2169.1672.593.1617.511.515.320.483172.4515.8910.49-30.8911.419.712.64
Amgen, Inc.23.97bn7.68bn151.91bn23.40k20.2316.0114.776.3412.7712.7739.8916.130.38141.445.461,024,188.0012.2110.8315.1812.6779.9181.7532.0234.011.2813.400.770541.54-1.623.09-6.588.74-9.2318.91
Eli Lilly And Co23.09bn5.53bn156.73bn33.63k27.1750.9123.456.796.036.0325.163.220.58371.564.49686,605.2013.998.7620.1012.2879.2276.6223.9716.770.86372.760.843564.423.842.6239.4514.17-2.875.65
AbbVie Inc34.06bn8.39bn174.26bn30.00k17.50--16.585.125.655.6522.94-5.020.46034.415.661,135,233.0011.409.9014.3512.7277.0677.1424.7721.343.039.091.1279.291.5710.7636.5534.62-2.0420.86
Pfizer Inc.50.66bn15.47bn191.70bn88.30k12.612.959.053.782.742.808.9911.710.31491.215.20573,725.909.636.2712.027.6880.3779.4030.5920.230.7765--0.444573.76-3.540.850354.1511.9110.386.72
Merck & Co., Inc.48.08bn10.20bn198.85bn71.00k19.827.5914.454.143.973.9618.7310.380.57492.326.09677,211.3012.186.5016.298.2772.1767.9321.1814.300.865728.970.515688.9810.752.0953.02-3.5321.405.13
Data as of Jul 03 2020. Currency figures normalised to Bristol-Myers Squibb Co's reporting currency: US Dollar USD

Institutional shareholders

32.93%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2020187.21m8.27%
BlackRock Fund Advisorsas of 31 Mar 2020113.33m5.01%
SSgA Funds Management, Inc.as of 31 Mar 2020100.85m4.46%
Wellington Management Co. LLPas of 31 Mar 202075.51m3.34%
Renaissance Technologies LLCas of 31 Mar 202065.99m2.92%
Fidelity Management & Research Co. LLCas of 31 Mar 202056.55m2.50%
Geode Capital Management LLCas of 31 Mar 202040.23m1.78%
JPMorgan Investment Management, Inc.as of 31 Mar 202038.17m1.69%
Dodge & Coxas of 31 Mar 202036.28m1.60%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202030.88m1.37%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.